PDF icon Download PDF
Open Access
CC BY 4.0 · TH Open 2025; 09: a26354840
DOI: 10.1055/a-2635-4840
Original Article

Venous Thromboembolism Therapy with Edoxaban in Daily Care Patients: Results from the DRESDEN NOAC REGISTRY

Luise Tittl
1   Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Christina Köhler
1   Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Sandra Marten
1   Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Christiane Naue
1   Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Jan Beyer-Westendorf
1   Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
› Author Affiliations
Funding The NOAC registry is supported by the Gesellschaft für Technologie- und Wissenstransfer der Technischen Universität Dresden (GWT-TUD GmbH), Germany (sponsor); by grants from Bayer AG, Boehringer Ingelheim, Pfizer, and Daiichi Sankyo. All authors declare that these companies and institutions had no influence on the study design, conduct of the study, data collection, statistical analysis, or preparation of the manuscript.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Direct oral anticoagulants such as edoxaban are standard of care in current treatment of venous thromboembolism (VTE). However, phase III trial data need confirmation in real-world settings.

We extracted data from the prospective, noninterventional multiple-indication DRESDEN NOAC REGISTRY to evaluate outcome rates during VTE treatment with edoxaban. Patients were included in this analysis, if they had acute VTE and if patient enrolment and edoxaban initiation occurred within 30 days after VTE diagnosis. Patient characteristics, treatment persistence, and clinical outcomes were centrally adjudicated using standard definitions.

Until December 31, 2023, 323 acute VTE patients (median age 67 years, 56.7% male) were enrolled and initiated edoxaban within 7.8 ± 4.9 days (mean) for isolated deep vein thrombosis (DVT) (57.6%) or pulmonary embolism (PE) ± DVT (42.4%). Mean duration of follow-up was 3.9 ± 1.9 years with a mean duration of edoxaban exposure of 1.5 ± 1.7 years. During ongoing edoxaban therapy, 3/323 patients (0.9%) experienced recurrent VTE (0.6/100 patient-years); 141/323 (43.7%) patients reported clinically relevant International Society on Thrombosis and Haemostasis (ISTH) nonmajor bleeding and 16 reported ISTH major bleeding (5.0%; 3.2/100 patient-years). Death was observed in 53 patients (4.1/100 patient-years). At 6 months, 78.2% were still taking edoxaban, 2% were electively switched to dose-reduced secondary prophylaxis with apixaban 2.5 mg twice a day or rivaroxaban 10 mg once daily. The remaining patients had a scheduled end of VTE treatment (11.4%) or were switched to nonedoxaban therapeutic anticoagulation (6.2%).

Our results indicate effectiveness of edoxaban in acute VTE treatment with excellent persistence in the treatment and low rates of unplanned discontinuation. Bleeding was frequently observed, but rates of major bleeding were low and comparable to phase III data.

Keywords

anticoagulation - bleeding - persistence - edoxaban - venous thromboembolism

Authors' Contributions

J.B.-W. and L.T. have designed this analysis. J.B.-W. has written the first draft of the manuscript. C.K., C.N., S.M., and L.T. have collected the data. L.T. has performed the statistical analyses and drafted the figures. All authors have provided significant contributions to the written presentation, have critically reviewed, and approved the final version of the manuscript.




Publication History

Received: 10 March 2025

Accepted: 08 May 2025

Article published online:
05 July 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Bibliographical Record
Luise Tittl, Christina Köhler, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf. Venous Thromboembolism Therapy with Edoxaban in Daily Care Patients: Results from the DRESDEN NOAC REGISTRY. TH Open 2025; 09: a26354840.
DOI: 10.1055/a-2635-4840
 

  • References

  • 1 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 2016; 149 (02) 315-352
    Search in Google Scholar
  • 2 Heidbuchel H, Verhamme P, Alings M. et al; European Heart Rhythm Association. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15 (05) 625-651
    Search in Google Scholar
  • 3 Daiichi Sankyo UK. Limited. Lixiana 60mg Film-Coated Tablets: Summary of product characteristics 2024. Accessed January 18, 2024 at: https://www.medicines.org.uk/emc/product/6905/smpc
  • 4 Bayer plc. Xarelto 20mg film-coated tablets: summary of product characteristics 2024. Accessed November 14, 2024 at: https://www.medicines.org.uk/emc/product/2793/smpc
  • 5 Bristol-Myers Squibb-Pfizer. Eliquis 5 mg film-coated tablets: Summary of product characteristics 2024. Accessed January 4, 2024 at: https://www.medicines.org.uk/emc/product/2878/smpc
  • 6 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    Search in Google Scholar
  • 7 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    Search in Google Scholar
  • 8 Ageno W, Mantovani LG, Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 3 (01) e12-e21
    Search in Google Scholar
  • 9 Beyer-Westendorf J, Marten S, Tittl L, Naue C, Bornhäuser M. Venous thromboembolism therapy with apixaban in daily care patients: results from the DRESDEN NOAC REGISTRY. TH Open 2021; 5 (02) e143-e151
    Search in Google Scholar
  • 10 Keller L, Marten S, Hecker J, Sahin K, Tittl L, Beyer-Westendorf J. Venous thromboembolism therapy with rivaroxaban in daily-care patients: results from the DRESDEN NOAC REGISTRY. Int J Cardiol 2018; 257: 276-282
    Search in Google Scholar
  • 11 Sindet-Pedersen C, Langtved Pallisgaard J, Staerk L. et al. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study. Thromb Haemost 2017; 117 (06) 1182-1191
    Search in Google Scholar
  • 12 Bott-Kitslaar DM, McBane RD, Casanegra AI. et al. Apixaban and rivaroxaban in patients with acute venous thromboembolism. Mayo Clin Proc 2019; 94 (07) 1242-1252
    Search in Google Scholar
  • 13 Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm 2020; 77 (03) 188-195
    Search in Google Scholar
  • 14 Agnelli G, Hoffmann U, Hainaut P. et al; ETNA-VTE-Europe investigators. ETNA-VTE Europe: benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thromb Res 2020; 196: 297-304
    Search in Google Scholar
  • 15 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
    Search in Google Scholar
  • 16 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    Search in Google Scholar
  • 17 Beyer-Westendorf J, Gelbricht V, Förster K. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective DRESDEN NOAC REGISTRY. Eur Heart J 2014; 35 (28) 1888-1896
    Search in Google Scholar
  • 18 Cohen AT, Hoffmann U, Hainaut P. et al; ETNA-VTE-Europe investigators. ETNA VTE Europe: a contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. Eur J Intern Med 2020; 82: 48-55
    Search in Google Scholar
  • 19 Marten S, Naue C, Tittl L, Bornhauser M, Beyer-Westendorf J. Long-term VTE treatment with rivaroxaban: results from the DRESDEN NOAC REGISTRY. Thromb Res 2021; 208: 181-189
    Search in Google Scholar
  • 20 Linnemann B, Blank W, Doenst T. S2k-Leitlinie–Diagnostik und Therapie der Venenthrombose und Lungenembolie. AWMF-Registernr; 2023.
  • 21 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    Search in Google Scholar
  • 22 Stevens SM, Woller SC, Kreuziger LB. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160 (06) e545-e608
    Search in Google Scholar
  • 23 Beyer-Westendorf J, Förster K, Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the DRESDEN NOAC REGISTRY. Blood 2014; 124 (06) 955-962
    Search in Google Scholar
  • 24 Beyer-Westendorf J, Förster K, Ebertz F. et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015; 17 (04) 530-538
    Search in Google Scholar